Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis.
A patient with plasma cell myeloma and amyloidosis presented with a severe bleeding disorder. There was laboratory evidence of fibrinolysis and severe deficiency of alpha-2 plasmin inhibitor. Treatment with epsilon aminocaproic acid was associated with diminished bleeding and marked increase in the plasmin inhibitor level. This is the first report of acquired alpha-2 plasmin inhibitor deficiency in the fibrinolytic state associated with amyloidosis.
D000368:Aged; D015119:Aminocaproic Acid / Q000627:therapeutic use; D000686:Amyloidosis / Q000097:blood* / Q000150:complications; D005260:Female; D005342:Fibrinolysis; D006474:Hemorrhagic Disorders / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications; D000979:alpha-2-Antiplasmin / Q000172:deficiency*
D000979:alpha-2-Antiplasmin; D015119:Aminocaproic Acid